Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037044 | 0.84 | NAMPT (0.51) | NAMPTHDAC1KDR | |
| SCHEMBL25639012 | 0.81 | NAMPT (0.48) | NAMPTHDAC1PDE2AKDR | |
| SCHEMBL17034782 | 0.80 | NAMPT (0.48) | NAMPTHDAC1CYP3A4SMN1; SMN2 | |
| SCHEMBL19068843 | 0.79 | NAMPT (0.56) | NAMPTHDAC1 | |
| SCHEMBL22098106 | 0.79 | NOTUM (0.47) | NAMPTHDAC1PDE2AKDR | |
| SCHEMBL30838602 | 0.78 | HDAC1 (0.47) | NAMPTHDAC1PDE2AKDRHRH3 | |
| SCHEMBL14959492 | 0.78 | HDAC1 (0.48) | NAMPTHDAC1HIF1ACYP3A4PDE2A | |
| SCHEMBL17106486 | 0.78 | NAMPT (0.46) | NAMPTHDAC1CYP3A4ROCK2PDE2A | |
| SCHEMBL1721216 | 0.77 | HDAC1 (0.46) | NAMPTHDAC1PDE2AKDR | |
| SCHEMBL29379757 | 0.77 | HDAC1 (0.46) | NAMPTHDAC1PDE2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | NAMPT 1845/4885HDAC1 1327/4885HIF1A 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.